Skip to main content
S&P 5007,649.29+0.15%DOW51,672.29-0.20%NASDAQ26,508.82+0.34%BTC$81,192.00+6.11%ETH$2,638.92+7.76%GOLD$4,420.40+0.47%OIL$95.61-1.67%
Smart Investors Daily
GN

NASDAQ · GNTA

Genenta Science S.p.A.

Healthcare · Biotechnology

$0.76

Down-$0.06 (-7.88%)

Updated Sep 18, 2026, 8:01 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.78M
P/E ratio
-3.05
Dividend yield
0.00%
52-week range
$0.55 – $2.58
Volume
40.46K
Avg. volume
666.12K

Price performance

GNTA price history

1M range · 20 trading sessions · Daily adjusted prices

GNTA closed at $0.76 after 20 trading sessions, down 36.13% for the selected period.

Last close
$0.76
Period change
-36.13%
Period low
$0.74
Period high
$1.26
Daily close
View OHLC price history
GNTA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 17, 2026$0.75$0.7679$0.7199$0.7640.46K
Sep 16, 2026$0.8698$0.9233$0.713$0.741375.94K
Sep 15, 2026$0.841$0.9047$0.8301$0.830154.31K
Sep 14, 2026$0.82$0.8527$0.82$0.8314127.21K
Sep 11, 2026$0.9341$0.9341$0.8402$0.840832.9K
Sep 10, 2026$0.933$0.99$0.8602$0.861328.96K
Sep 9, 2026$0.9891$1.00$0.82$0.8725113.12K
Sep 8, 2026$0.9603$1.00$0.9603$0.991138.15K
Sep 4, 2026$0.9373$0.99$0.9373$0.960131.64K
Sep 3, 2026$1.00$1.00$0.9505$0.950552.24K
Sep 2, 2026$1.02$1.0299$0.97$0.978123.45K
Sep 1, 2026$1.04$1.04$0.98$1.0130.15K
Aug 31, 2026$1.03$1.03$0.9999$1.0224.78K
Aug 28, 2026$1.02$1.0799$1.00$1.0058.85K
Aug 27, 2026$1.13$1.1774$0.9907$0.990789.75K
Aug 26, 2026$1.1612$1.17$1.11$1.1341.66K
Aug 25, 2026$1.15$1.20$1.10$1.1582.79K
Aug 24, 2026$1.20$1.23$1.15$1.1543.95K
Aug 21, 2026$1.22$1.29$1.22$1.2628.51K
Aug 20, 2026$1.2097$1.27$1.18$1.1933.67K

Latest GNTA news

The latest Smart Investors Daily articles mentioning GNTA.

Stock researchCompany · Overview

GNTA research

Overview

Company profile and research snapshot.

Company profile

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GNTA recent ratings
DateFirmRatingTarget
Oct 2, 2024HC Wainwright & Co.Buy—
May 13, 2024HC Wainwright & Co.Buy—
Feb 8, 2023HC Wainwright & Co.Buy—
Jan 5, 2023EF HuttonBuy—
Jul 25, 2022HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 15, 2026

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

The Spring Assembly manufactured by Sòphia HT, a strategic Genenta investment, supports the separation of the launcher’s second and third stages Sòphia HT has been in serial production of the component since 2018 MILAN, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on aerospace, defense, national security and biotechnology, today announced that Sòphia High Tech S.r.l. (Sòphia HT), the Italian ae

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By